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ABSTRACT
Hospital acquired infections (HAIs) are mostly caused by Gram-negative organisms and is one of the major issues in patient safety. These infections 
are often associated with the medical processes of hospitals such as invasive medical devices and various surgical procedures. Gram-negative 
organisms account for most infections in the hospital environment because of their ability to acquire resistant against multiple antibiotics. Through 
different mechanisms including the synthesis of β- lactamases, overexpression of transmembrane efflux pump, loss of porins, synthesis of antibiotic 
modifying enzymes, target mutations, ribosomal mutation or modifications, mutations in lipopolysaccharide structure etc. these organisms have 
developed drug-resistant property and the genes encoded in plasmids play a vital role in developing the resistant. Among all Gram-negative bacteria, 
Acinetobacter baumannii is an emerging pathogen that accounts for about 80% of all reported infections. Although other species of Acinetobacter are 
also often associated with HAIs. Acinetobacter is non-motile, obligate aerobic Gram-negative coccobacillus and are ubiquitous free-living saprophytes 
in soil and water. It is commonly transmitted through medical devices such as ventilators, urinary catheters and other invasive devices in hospitals 
but its ability to colonize on the skin of individuals often increases the rate of transmission through person to person contact. Patients admitted to 
Intensive Care Unit (ICU) are at the major risk of getting infected by A. baumannii and these includes pneumonia/ventilator associated pneumonia 
(VAP), bloodstream infections, wound abscesses, urinary tract infections etc.
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INTRODUCTION
Hospital-acquired infection (HAI) also called nosocomial infection 
is a kind of infection which is acquired in the hospital by a patient 
in whom the infection was not present at the time of admission but 
emerged after discharging, and it also includes occupational infections 
among the staff of the organization [1,2]. Nosocomial infections are 
mostly caused by Gram-negative organisms and are one of the major 
issues in patient safety. HAIs are one of the major causes of death [3] 
which have worldwide prevalence and affect developed, developing, 
and resource-poor countries. The rate of morbidity and mortality 
is significantly increased and cause financial losses for health-care 
system. The study has revealed that within hospital it is mostly 
prevalent is intensive care units (ICUs) followed by acute surgical and 
orthopedic wards [4], approximately, 30% patients in ICU are affected 
by at least one nosocomial infection [5]. Most frequent causative 
agents are Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella 
pneumoniae and Acinetobacter baumannii (Ab). Over the last 15 years, 
Ab has emerged as a potent nosocomial pathogen. It became the second 
most common Gram-negative bacilli after P. aeruginosa to be isolated 
from clinical specimens, and they rank fourth after (P. aeruginosa, 
S. aureus, K. pneumoniae) as most frequent hospital-acquired infectious 
agents. From the last two decades, clinicians worldwide have identified 
Acinetobacter genus, especially Ab as a frequent organism associated 
with critically ill patients [6].
HISTORICAL ANALYSIS OF THE GENUS ACINETOBACTER
In the early 20th century (1911), a Dutch microbiologist, Beijerinck, 
isolated an organism from the soil by a culture medium that was enriched 
by calcium acetate and named it as Micrococcus calcoaceticus [7]. Similar 
organisms were described and allotted to 15 different genera and 
species over the following years. In 1954, Brisou and Pre´vot proposed 
the current taxonomic genus, i.e., Acinetobacter. In Greek, it means 
non-motile. Brisou and Pre´vot separated the non-motile organisms 
from those of motile organisms within the genus Achromobacter [8]. 
However, this was not widely accepted until Baumann et al. concluded 
that the previously isolated organisms belonged to a single genus for 
which the name Acinetobacter was proposed. These findings led the 
genus Acinetobacter for an official acknowledgment in 1971 by the 
Sub-committee on the Taxonomy of Moraxella and Allied Bacteria. 
In the 1974 edition of Bergey’s Manual of Systematic Bacteriology, 
the genus Acinetobacter was listed, with the description of a single 
species, Acinetobacter calcoaceticus [7]. In the “Approved List of 
Bacterial Names,” in contrast, two different species, A. calcoaceticus 
and Acinetobacter lwoffii, were included, based on the observation that 
some Acinetobacters were able to acidify glucose whereas others were 
not [10]. Current taxonomic nomenclature defined as Acinetobacter 
is within the family Moraxellaceae and order Gammaproteobacteria, 
which includes the genera Moraxella, Acinetobacter, Psychrobacter, and 
related organisms [9].
GENERAL DESCRIPTION OF THE GENUS ACINETOBACTER
They are Gram-negative nonmotile coccobacilli possess very minimum 
growth requirement. They are strictly aerobe and cannot tolerate 
anaerobic condition but can survive on a variety of surfaces and 
aquatic environment. Acinetobacter is non-fermenter but has oxidizing 
properties. They are catalase positive and oxidase negative organism. 
DNA contains 39-47% of G+C content. They are a part of the commensal 
flora of human and animal which are regular contaminants of the 
hospital environment. Up to 25% of healthy ambulatory adults exhibit 
cutaneous colonization by Acinetobacter and are the most common 
Gram-negative bacteria carried on the skin of hospital personnel [11].
SOURCE AND OCCURRENCE
They are ubiquitous in nature, and inhabitants of soil, water, and sewage 
water as well. They are found mostly in aquatic environment. About 97% 
of natural water sample has been isolated with Acinetobacter spp. The 
bacterial count reached up to 100/ml. The organisms have been found 
to represent 1.0-5.5% of the HPC flora in drinking-water samples and 
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have been isolated from 5% to 92% of distribution water samples [12]. 
In the USA, one survey from untreated ground water has been isolated 
with the Acinetobacter spp. found in 38% of water supplies. They 
are the producer of slime layer, and there are no differences in the 
slime production of Acinetobacter spp. isolated from water samples 
and clinical specimens. Acinetobacter spp. are the normal flora of 
skin and occasionally in the respiratory tract of healthy individuals. 
Ingestion of drinking water having Acinetobacter spp. do not cause 
gastrointestinal infections; however, it can cause non-gastrointestinal 
problems in susceptible patients and individuals associated with 
health-care settings. Acinetobacter spp. are susceptible to chlorine, 
so uses of disinfectants can limit the transmission of organism. In an 
epidemiological survey performed to investigate the colonization of 
human skin and mucous membranes with Acinetobacter species, up 
to 43% of non-hospitalized individuals were found to be colonized 
with these organisms while in hospitalized patients the carriage rate 
of Acinetobacter spp. were comparatively high, i.e., 75% [13]. The 
fecal carriage rate of Acinetobacter spp. were detected up to 25% by 
Dijkshoorn et al. and the predominant species were Acinetobacter 
johnsonii and Acinetobacter genomic species 11 [15]. Chu et al. 
found 53% of medical students and new nurses to be colonized with 
Acinetobacters in summer versus 32% in winter [16]. These seasonal 
variations are associated with the prevalence of Ab infections. Ab was 
recovered from 22% of body lice sampled from homeless people [14]. 
Acinetobacters are capable of surviving on inanimate substances for a 
longer period. Berlau et al. investigated vegetables in the United Kingdom 
and found that 30 of 177 vegetables (17%) were culture positive 
for Acinetobacter [17]. Interestingly, Ab and Acinetobacter genomic 
species 11 (each at 27%) were the predominant species, followed by A. 
calcoaceticus and Acinetobacter genomic species 3 (each at 13%), while 
Acinetobacter genomic species 13 was found only once. In Hong Kong, 
51% of local vegetables were culture positive for Acinetobacter species, 
the majority of which were Acinetobacter genomic species 3 (75%), 
but one sample grew Ab [18]. Houang et al. found Acinetobacters in 22 
of 60 soil samples in Hong Kong, and the most frequent species were 
Acinetobacter genomic species 3 (27%) and Ab (23%), with only one 
sample yielding A. calcoaceticus [18].
LOAD OF ACINETOBACTER SPP. IN HOSPITAL ENVIRONMENT
Several studies have shown the prevalence of Acinetobacter spp. 
in hospital environment but their rate of occurrence vary widely 
depending on the protective actions and safety measures taken by 
different hospitals. The presence of Acinetobacter spp. has been found 
in almost all part of hospital which includes sinks, floors, cupboards, 
linens, mattresses, ventilators, and respirators. Contamination of 
mattresses occurs through breaches in plastic covers that allowed 
water penetration and persistence of the organism in the wet foam 
of the mattresses. More recently, feather pillows were found to be 
contaminated with considerable numbers of Acinetobacter in an 
outbreak of infection in the Netherlands [19]. It suggests that these 
inanimate things play a major role in transmission of Acinetobacter spp. 
which contributes them to be a potent nosocomial pathogen. It has 
been reported that Acinetobacter cells can survive on dry surfaces 
for durations even longer than that found for S. aureus [20,21]. An 
epidemic strain of multi drug resistant (MDR) Acinetobacter spp. has 
been shown to survive for up to 6 days after inoculation on to dry filter 
paper, duration similar to that found with S. aureus, which persisted for 
7 days while P. aeruginosa and Escherichia coli survives up to 24 hrs or 
less [22]. Their ability to survive in all most all inanimate substances 
and minimal nutritional requirements make them very common 
nosocomial pathogen associated with outbreaks. The outbreaks also 
occur when the patient has some underlying disease and various 
medical processes have implicated, for example, intravenous catheters, 
respirators, and peritoneal dialysis. [23].
ROUTES OF TRANSMISSION
Environmental sources and cross-transmissions are the most common 
cause of transmission of Acinetobacter infections. Possible routes 
include direct contact, burn and inhalation especially in ICUs where 
patients are on mechanical ventilation. In patients with Acinetobacter 
bacteremia, intravenous catheters have also been identified as a source 
of infection. Water baths and humidifiers are also a potent source of 
infection. The oral transmission (through ingestion) is not a usual 
source of infection.
FACTORS CONTRIBUTING TO ESTABLISH A WELL FORMED 
DISEASE
Acinetobacter infections are favored by these following factors:
• Ability to upregulate and acquiring resistance gene which enable 
them to resist mostly all common antibiotics used in health-care 
setting, and enable them to become MDR bacteria.
• They are part of commensal flora which facilitates the cross-
transmission.
• Their nonfastidious property helps them to survive on various 
inanimate materials as well as in aqueous environment.
• Underlying disorders, for example, long-term diabetes mellitus, 
immunocompromised state such as in patients with HIV infection 
can enhance the risk of Acinetobacter infections.
• Drug therapies such as immunosuppressive drugs and antibiotics, 
chemotherapy, radiotherapy, current surgeries, endotracheal 
intubation, intravenous procedures, catheterization contribute 
toward easy development of infection as all mentioned procedures 
suppress the immunity and make a route for easy entry.
SPECIES OF MEDICAL IMPORTANCE
Several studies have revealed that among all the different species, Ab 
is the most common nosocomial pathogen found in mostly all clinical 
specimens and are associated with major complications, for example, 
respiratory tract infections, and septicemia. According to the data of 
Centers for Disease Control and Prevention, the species Ab accounts for 
nearly 80% of reported Acinetobacter infection. Acinetobacter genomic 
species 3 and 13TU have been implicated in nosocomial outbreaks while 
A. johnsonii has been associated with catheter-associated bacteremia. 
A. calcoaceticus- Ab complex [24,25] contains isolates that are mostly 
glucose acidifying. The majority of glucose-negative, nonhemolytic 
strains found in clinical specimens seem to be identified mainly as 
A. lwoffii, A. johnsonii, Acinetobacter haemolyticus is the species who 
shows hemolysis. Other groups seem to be implicated only occasionally 
in human infections.
CLINICAL CASES ASSOCIATED WITH ACINETOBACTER SPP.
Acinetobacter spp. are associated with various clinical cases which 
sometimes is often fatal. Their abundant occurrence in nature and 
minimal nutritional requirement make them a potent pathogen to cause 
a well-formed infection. They occur mostly in the ICUs, as most of the 
patients are on ventilation. A mechanical ventilator is a potent source 
of infection, and it contributes as a source of transmission. Ventilator-
associated pneumonia and ICU-acquired pneumonia are frequent 
cases occurred in ICUs. Post-surgical abscess and wound infections, 
bacteremia and septicemia as a result of the surgical and medical 
process, urinary tract infections on catheterization, pleural effusion, 
peritonitis, and meningitis are associated with Acinetobacter infections.
HEALTH IMPACT OF ACINETOBACTER INFECTIONS
MDR strains are associated with critically ill patients. This property 
to resist approximately all common antibiotics set the mortality 
rate at a high level, i.e., 26-68% [26-28]. Acinetobacter infections 
and colonization are associated with increased mortality [29-31]. 
Other studies that rigorously controlled for severity of illness did 
not find Acinetobacter infection to be independently associated with 
increased mortality [26,32-34]. However, patients with deliberated 
underlying illness the organism can be responsible for high mortality 
rate individually. Acinetobacter infection is associated with increased 
morbidity and a prolonged length of hospital stay. The duration of 
hospital stay is directly associated with the related infections caused 
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by Acinetobacter spp. and MDR- Acinetobacter spp. Patients with 
Acinetobacter bacteremia had a 5 days excess length of mechanical 
ventilator dependence and ICU stay, compared with critically ill 
patients without Acinetobacter infection [33]. The severity of infections 
is depended on the length of hospital stay and degree of antibiotic-
resistant.
MECHANISM OF ANTI-MICROBIAL RESISTANCE
Acinetobacter spp. are emerging as a potent threat to hospitalized 
patients as they are untreatable with the most common antibiotics. 
The trend to resist the drugs has been extremely enhanced form past 
two decades. Ab among all species has been developed itself as a most 
common and also as a super bug associated with nosocomial infections. 
Upregulation of innate resistance, for example, impermeable outer 
membrane and acquisition of resistance gene are two major skill used by 
this bacteria that helps it to become a deadly pathogen in mainly health-
care facility. Their natural habitat is also contributing them to achieve 
easy transmission of infection. MDR - Ab is very common problem to the 
physician to treat the patients especially having respiratory problems 
and associated with ICU units. MDR - Acinetobacter can be defined in 
two ways, i.e., resistance to carbapenem or resistance to ≥3 classes 
of antibiotics [35]. Some strains are only treatable with polymyxin, 
but resistance to them is also been reported in literature. The rapid 
emergencies of resistant strains of Acinetobacter globally possess the 
treatment option limited and crucial. In three possible ways, they resist 
the drugs, i.e., production of enzymes that degrade the antimicrobial 
substances, mutation that changes the bacterial target sites, and 
alteration in cellular function, for example, efflux pump [36].
They produce a wide variety of β-lactamases, enzymes that degrade 
the β-lactam ring. This enzyme confers resistance to penicillins, 
cephalosporins, and carbapenems. They resist broad-spectrum 
cephalosporins by AmpC cephalosporinase enzyme that is encoded 
in chromosome [40,41]. Class B metallo-β-lactamases (MBLs) are 
expressed in certain strains which provide them to resist a wide 
range of antimicrobial agent including carbapenems [37]. MBLs are 
easily transferred among bacteria which possess a great chance to 
get resistant genes easily. Acinetobacter spp. are well known for their 
resistance capability through alteration in bacterial targets. Porin 
channels and outer membrane proteins are the way for the drug to 
reach their targets, alteration in these structures enabling them to be a 
deadly pathogen that resist all kind of drugs. Loss of proteins from the 
outer membrane is linked with carbapenem-resistant Ab (CR-Ab) [37]. 
Various efflux systems are associated with Ab, for example, AdeABC, 
AdeM, Tet(A), Tet(B). Resistance to colistin is thought to be mediated by 
changes in the bacterial cell membrane that interfere with the agent’s 
ability to bind bacterial targets [38]. Acinetobacter spp. can acquire 
genes from Pseudomonas spp. Salmonella spp., etc. A study have shown 
an interesting fact that in France MDR - Acinetobacter strain consist 
of a resistance island containing approximately 45 resistant gene and 
that appeared to have been acquired from species of Pseudomonas, 
Salmonella, and Escherichia [39]. Another study has been done on 
CR property of Ab and a total of 51 clinically significant CR-Ab were 
isolated from different specimens including tracheal aspirate, blood, 
wound sample and urine during t 4 months. Modified Hodge’s test 
detected carbapenemase production in 50 out of 51 (98%) isolates, 
whereas ethylenediaminetetraacetic acid-disk synergy test detected 
MBLs production in 48 out of 51 (94.1%) isolates [42]. These findings 
support that since last two decades Ab has been emerged as a potent 
nosocomial pathogen.
MANAGEMENT OF MDR-ACINETOBACTER
Like all living organisms, microbes face challenges to their own survival 
as in their environmental and ecological changes. Because of this 
reason they acquire, develop or evolve mechanisms that favor them 
to survive in their surroundings. Their short life cycle opens infinite 
opportunities for genetic mutation to occur. In the other hand, their 
ability to acquire gene and sharing genes among related and unrelated 
species facilitate their existence. These properties enable them to 
respond to environmental as well as ecological changes. Hence, the 
antibiotic therapy in the health-care system can actually change the 
ecological atmosphere which can trigger the development of resistant 
strains. Thus, the uses of antibiotics should be minded and only used 
at proper dose. Fishman has described some strategies by which these 
consequences can be controlled which include education, formulary 
restriction, streamlining, and antibiotic cycling. All of them restrict the 
unnecessary uses of antibiotics, uses of broad spectrum antibiotics, 
continuous use of one antibiotic which can limit the occurrence 
antibiotic resistant strains.
Infectious Diseases Society of America and the Society for Healthcare 
Epidemiology of America recommend two core strategies for 
antimicrobial stewardship programs as per 2007 guidelines which says 
that prospective audit of antimicrobial use with direct interaction and 
feedback to the prescribing physician and formulation restriction and 
pre- authorization requirements can lead to significant reductions in 
antimicrobial use. To manage the load of MDR-Acinetobacter, analysis 
of susceptibility and antibiogram are at the major concern. Each MDR-
Acinetobacter isolate must be checked for susceptibility and it should 
be readily accessible by physicians. They are helpful in both patient care 
treatments and surveillance of MDR-Acinetobacter.
Antibiogram often deals with the drug pattern of many isolates derived 
from clinical specimens rather consider for a single isolate. Compilation 
of drug pattern is generally done by the microbiology laboratory 
using data from various units. In case of Ab, susceptibility results 
from different isolates are compiled during a specific period and must 
be updated annually. The resulting antibiogram suggests the choice 
of drug for treatment of Acinetobacter associated infections in that 
particular unit. They can be used by physician to control the infection 
when the susceptible result is yet not available for patients. It also used 
in monitoring the changes of drug susceptibility. In one study, isolate of 
Ab obtained from Brahmakumari Hospital was subjected to antibiotic 
susceptibility testing to get the antibiogram. None of isolates gave the 
zone of inhibition at all to cefotaxime, they so considered as extended 
spectrum beta-lactamases. A synergy of cefotaxime and Terminalia 
chebula has been tested and it has been observed that there was a zone 
of inhibition formed [43]. This study indicates that the combination 
of medicinal plant extracts and known antibiotics offers significant 
potential for the development of novel antimicrobial therapies [43].
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